Elsaadi et al. [56] showed that myeloma cells treated with NCT-503 had reduced intracellular redox capacity and that inhibition of PHGDH provided a therapeutic advantage in vivo when combined with proteasome inhibitor bortezomib. The gene discussed is PHGDH; the disease is plasma cell myeloma.